Sensus Healthcare, Inc. (SRTS) Stock Analysis

Sensus Healthcare’s primary competitive advantage lies in its proprietary Superficial Radiation Therapy (SRT) technology, which offers a non-invasive alternative to Mohs surgery for non-melanoma skin cancer. The company’s SRT-100 product line is protected by patents, including workflow management and imaging fusion (e.g., Patent No. 11,894,123 B2), and has received FDA clearance and dedicated CPT reimbursement codes—an important regulatory barrier that is difficult for new entrants to replicate. The recent introduction of exclusive CPT codes (effective 2026) has improved reimbursement certainty, directly enhancing the value proposition for physicians and accelerating adoption.

Sensus benefits from high switching costs among its installed base (955 units as of year-end 2025), as clinics invest in training and workflow integration. Recurring revenue from service contracts further increases customer stickiness, supporting gross margins historically above 50%. However, the company’s moat is narrow: Mohs surgery remains the entrenched standard of care, with higher cure rates and broad physician acceptance. Direct device competitors such as Xstrahl offer similar SRT systems, and larger firms like Elekta and Siemens Healthineers possess greater scale, R&D resources, and global reach.

Sensus’s focused niche and regulatory achievements provide a defensible position in dermatology, but its small scale, modest R&D budget, and reliance on a single product category limit its long-term resilience relative to diversified, better-capitalized rivals.